ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.86
-0.10 (-1.51%)
Apr 29, 2026, 3:09 PM EDT - Market open
ImmunityBio Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 7,079 | 1,950 | 1,869 | 3,352 | 2,076 | 2,419 | |
| Market Cap Growth | 226.10% | 4.33% | -44.23% | 61.49% | -14.18% | - | |
| Enterprise Value | 7,692 | 2,555 | 2,759 | 3,882 | 2,676 | 2,681 | |
| Last Close Price | 6.96 | 1.98 | 2.56 | 5.02 | 5.07 | 6.08 | |
| PS Ratio | 62.58 | 17.22 | 126.77 | 5388.88 | 8648.47 | 2589.53 | |
| PB Ratio | - | -3.90 | -3.83 | -5.72 | -4.61 | -9.92 | |
| EV/Sales Ratio | 67.89 | 22.55 | 187.09 | 6241.20 | 11149.27 | 2870.55 | |
| Debt / Equity Ratio | -1.69 | -1.69 | -1.62 | -1.51 | -1.61 | -2.66 | |
| Net Debt / Equity Ratio | -1.20 | -1.20 | -1.31 | -1.05 | -1.37 | -1.35 | |
| Net Debt / EBITDA Ratio | -2.50 | -2.50 | -1.96 | -1.80 | -1.86 | -1.09 | |
| Net Debt / FCF Ratio | -1.95 | -1.95 | -1.61 | -1.55 | -1.48 | -1.07 | |
| Asset Turnover | 0.26 | 0.26 | 0.03 | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.16 | 0.16 | - | - | - | - | |
| Quick Ratio | 4.62 | 4.62 | 2.78 | 4.63 | 0.22 | 0.86 | |
| Current Ratio | 5.10 | 5.10 | 3.36 | 5.05 | 0.28 | 0.91 | |
| Return on Assets (ROA) | -36.17% | -36.17% | -48.48% | -52.11% | -52.73% | -57.48% | |
| Return on Capital Employed (ROCE) | -58.20% | -58.20% | -104.90% | -81.00% | 253.20% | -317.70% | |
| Earnings Yield | -4.96% | -18.02% | -22.13% | -17.40% | -20.07% | -14.34% | |
| FCF Yield | -4.36% | -15.83% | -21.30% | -11.85% | -20.03% | -12.73% | |
| Buyback Yield / Dilution | -31.33% | -31.33% | -37.71% | -27.19% | -2.74% | -3.23% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.